CSIMarket
 
Kalvista Pharmaceuticals Inc   (KALV)
Other Ticker:  
 
 

Kalvista Pharmaceuticals Inc's Suppliers Performance

KALV's Supply Chain

 
KALV Costs vs Sales of Suppliers Growth

More on KALV Suppliers






  News about Kalvista Pharmaceuticals Inc Contracts

KalVista Pharmaceuticals Evolving HAE Treatment with Real-World Data and Innovations

In recent updates, KalVista Pharmaceuticals, a clinical stage pharmaceutical company, has presented new findings and data at various conferences, emphasizing the impact of treatment delays on the clinical outcomes of individuals living with hereditary angioedema (HAE). Moreover, the company has showcased additional data from its phase 3 KONFIDENT trial, shedding light on the efficacy and safety of sebetralstat, an oral plasma kallikrein inhibitor. Furthermore, KalVista has been awarded the UK Innovation Passport for sebetralstat by the Medicines and Healthcare products Regulatory Agency (MHRA).KalVista Pharmaceuticals has made significant progress in the field of HAE treatment, presenting crucial real-world ...

KalVista Pharmaceuticals Sets Promising New Paradigm in Hereditary Angioedema Treatment, Progressing with Clinical Trials and Achieving Financial Milestones

KalVista Pharmaceuticals Advances in Clinical Trials and Financial Performance, Pursuing Promising Therapies for Hereditary AngioedemaCAMBRIDGE, Mass. and SALISBURY, England- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a renowned clinical-stage pharmaceutical company specializing in the discovery, development, and commercialization of oral, small molecule protease inhibitors, recently provided an operational update and shared financial results for the third fiscal quarter concluding on January 31, 2024. This period has proven to be exceptionally busy and rewarding for KalVista, as the company accomplished significant milestones in its phase 3 KONFIDENT trial. Having previously announced the achievement of...

Sebetralstat: KalVista Pharmaceuticals' UK Innovation Passport Grants Green Light for Breakthrough Hereditary Angioedema Treatment

In a recent development, KalVista Pharmaceuticals, a renowned clinical stage pharmaceutical company, has been granted the UK Innovation Passport for its novel investigational drug, sebetralstat. This oral plasma kallikrein inhibitor has shown promising potential for the on-demand treatment of hereditary angioedema (HAE), a rare and potentially life-threatening genetic disorder. The recognition by the UK Medicines and Healthcare products Regulatory Agency (MHRA) brings significant opportunities and implications for both the company and HAE patients worldwide.Facts and Impact:1. KalVista Pharmaceuticals (NASDAQ: KALV), based in Cambridge, Massachusetts, and Salisbury, England, has been working diligently towar...




Kalvista Pharmaceuticals Inc's Comment on Supply Chain









KALV's vs. Suppliers, Data

(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)



COMPANY NAME MARKET CAP REVENUES INCOME EMPLOYEES
Kalvista Pharmaceuticals Inc 412.37 12.69 -100.58 -
SUBTOTAL 0.00 0.00 0.00 -


Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com